Integrated Filing — IndAS



General information about company
Scrip Code 000000
NSE Symbol ZOTA
MSEI Symbol NOTLISTED
ISIN INE358U01012
Name of company ZOTA HEALTH CARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Manufacturing and marketing of pharmaceutical products
Start date and time of board meeting 29-May-2025   14:00:00
End date and time of board meeting 29-May-2025   20:05:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-01-09
Indicate Company website link for updated RPT policy of the Company https://www.zotahealthcare.com/wp-content/uploads/2025/05/Related-Party-Transactions-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
During the quarter, the Company has not made any default on repayment of Loan. nFurther, the Company has not issued any Debt Securities till date.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 779325000 2572761000
Other income 14953000 46233000
Total income 794278000 2618994000
2 Expenses
(a) Cost of materials consumed 60903000 162276000
(b) Purchases of stock-in-trade 557795000 1553050000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -144569000 -161425000
(d) Employee benefit expense 88675000 311497000
(e) Finance costs 793000 10559000
(f) Depreciation, depletion and amortisation expense 9437000 31711000
(f) Other Expenses
1 Other Expenses 177049000 592893000
Total other expenses 177049000 592893000
Total expenses 750083000 2500561000
3 Total profit before exceptional items and tax 44195000 118433000
4 Exceptional items 0 0
5 Total profit before tax 44195000 118433000
6 Tax expense
7 Current tax 20391000 33563000
8 Deferred tax -2229000 -1302000
9 Total tax expenses 18162000 32261000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 26033000 86172000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 26033000 86172000
17 Other comprehensive income net of taxes 458000 1429000
18 Total Comprehensive Income for the period 26491000 87601000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 286350000 286350000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 2887337000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.92 3.16
Diluted earnings (loss) per share from continuing operations 0.86 2.91
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.92 3.16
Diluted earnings (loss) per share from continuing and discontinued operations 0.86 2.91
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) As per attaachment



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 84561000
Capital work-in-progress 55758000
Investment property 0
Goodwill 0
Other intangible assets 37962000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 1162395000
Trade receivables, non-current 0
Loans, non-current 592196000
Other non-current financial assets 0
Total non-current financial assets 1754591000
Deferred tax assets (net) 1566000
Other non-current assets 0
Total non-current assets 1934438000
2 Current assets
Inventories 595553000
Current financial asset
Current investments 0
Trade receivables, current 1030388000
Cash and cash equivalents 52000
Bank balance other than cash and cash equivalents 13446000
Loans, current 179378000
Other current financial assets 0
Total current financial assets 1223264000
Current tax assets (net) 0
Other current assets 43974000
Total current assets 1862791000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 3797229000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 286350000
Other equity 2887337000
Total equity attributable to owners of parent 3173687000
Non controlling interest
Total equity 3173687000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 0
Total non-current financial liabilities 0
Provisions, non-current 17934000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 17934000
Current liabilities
Current financial liabilities
Borrowings, current 2046000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 124817000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 337444000
Total Trade payable 462261000
Other current financial liabilities 0
Total current financial liabilities 464307000
Other current liabilities 75956000
Provisions, current 65345000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 605608000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 623542000
Total equity and liabilites 3797229000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) As per attachment



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 DEFINED BENEFIT PLAN 612000 1911000
Total Amount of items that will not be reclassified to profit and loss 612000 1911000
2 Income tax relating to items that will not be reclassified to profit or loss 154000 482000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 458000 1429000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 118433000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0
Adjustments for decrease (increase) in inventories -194939000
Adjustments for decrease (increase) in trade receivables, current -293265000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -20250000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current -52316000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 153852000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 95102000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 31711000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 6156000
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 5947000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -268002000
Net cash flows from (used in) operations -149569000
Dividends received 0
Interest paid -4976000
Interest received -43506000
Income taxes paid (refund) 34045000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -222144000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 42594000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets -1094696000
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties -384689000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 43506000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -1478473000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 1511448000
Proceeds from issuing other equity instruments 378345000
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings -144721000
Repayments of borrowings 0
Payments of lease liabilities 0
Dividends paid 27408000
Interest paid 4976000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 1712688000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 12071000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 12071000
Cash and cash equivalents cash flow statement at beginning of period 1428000
Cash and cash equivalents cash flow statement at end of period 13499000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Pradeep K Singhi & Associates Yes 31-Jan-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 14-Aug-2024
Amount Raised 962360000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review The Committee has noted that there is no deviation or variation.
Comments of the auditors, if any No comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of DAVAINDIA Project Not Applicable 1432583000 0 694872000 0 Note: Out of the issue proceeds of Rs 17907.28 lakhs, the Company has received issue proceeds of Rs 9623.60 lakhs till the quarter ended March 31, 2025. Further, the balance amount Rs 8283.65 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.
2 Working capital requirement Not Applicable 268609000 0 191887000 0 Note: Out of the issue proceeds of Rs 17907.28 lakhs, the Company has received issue proceeds of Rs 9623.60 lakhs till the quarter ended March 31, 2025. Further, the balance amount Rs 8283.65 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.
3 General Corporate Purpose Not Applicable 89536000 0 15600000 0 Note: Out of the issue proceeds of Rs 17907.28 lakhs, the Company has received issue proceeds of Rs 9623.60 lakhs till the quarter ended March 31, 2025. Further, the balance amount Rs 8283.65 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 20-Feb-2025
Amount Raised 771313000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review The Committee has noted that there is no deviation or variation.
Comments of the auditors, if any No comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of DAVAINDIA Project FOFO Not Applicable 160433000 0 92807000 0 Note: Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 3559.13 lakhs till the quarter ended March 31, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e., August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.
2 Expansion of DAVAINDIA Project COCO Not Applicable 765142000 0 210389000 0 Note: Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 3559.13 lakhs till the quarter ended March 31, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e., August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.
3 Working capital requirement Not Applicable 123410000 0 52717000 0 Note: Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 3559.13 lakhs till the quarter ended March 31, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e., August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.
4 General Corporate Purpose Not Applicable 185115000 0 0 0 Note: Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 3559.13 lakhs till the quarter ended March 31, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e., August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.


Signatory Details
Name of signatory Ashvin Variya
Designation of person Company Secretary and Compliance Officer
Place Surat
Date 29-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Zota Health Care Limited Himanshu Muktilal Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month and Commission on sales, 0.1% of annual turnover 3645000 1221000 834000
2 Zota Health Care Limited Kamlesh Rajnikant Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month and Commission on sales, 0.1% of annual turnover 3620000 1262000 879000
3 Zota Health Care Limited Moxesh Ketanbhai Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month and Commission on sales, 0.1% of annual turnover 3615000 1287000 904000
4 Zota Health Care Limited Ketan Chandulal Zota Non Executive Chairman Any other transaction Sitting Fees Noted 45000 18000 5000
5 Zota Health Care Limited Varshabahen Gaurang Mehta Non Executive Independent Director Any other transaction Sitting Fees Noted 90000 32000 18000
6 Zota Health Care Limited Vitrag Sureshkumar Modi Non Executive Independent Director Any other transaction Sitting Fees Noted 75000 27000 9000
7 Zota Health Care Limited Bhumi Maulik Doshi Non Executive Independent Director Any other transaction Sitting Fees Noted 75000 27000 9000
8 Zota Health Care Limited Dhiren Prafulbhai Shah Non Executive Independent Director Any other transaction Sitting Fees Noted 70000 23000 18000
9 Zota Health Care Limited Jayshreeben Nileshkuamr Mehta Non Executive Independent Director Any other transaction Sitting Fees Noted 75000 23000 23000
10 Zota Health Care Limited Dr. Sujit Paul Key Managerial Personnel Any other transaction Salary & Commission Basic remuneration of Rs. 2.28 crore per annum, commission of 0.1% of annual consolidated turnover, performance linked commission upto Rs. 20 lakh per annum and 2(two) fully paid up International tour of which cost not exceeding Rs 25 lakhs per tour 14150000 13000 3768000
11 Zota Health Care Limited Ashvin Variya Key Managerial Personnel Any other transaction Salary Salary upto Rs. 30 lakh per annum 1500000 187000 206000
12 Zota Health Care Limited Viral Mandviwala Key Managerial Personnel Any other transaction Salary Salary upto Rs. 14 lakh per annum 689000 104000 97000
13 Zota Health Care Limited Viren Manukant Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month and Commission on sales, 0.1% of annual turnover 3625000 1287000 909000
14 Zota Health Care Limited Niral M. Zota Promoter Group Any other transaction Salary & Commission Salary of Rs. 0.70 lakh per month and Commission on sales, 0.2% of annual turnover 1450000 1049000 522000
15 Zota Health Care Limited Heli R. Shah Promoter Group Any other transaction Salary Salary of Rs. 0.15 per month 65000 12000 11000
16 Zota Health Care Limited Davaindia Health Mart Limited Subsidiaries Sale of goods or services 2000000000 Approved 531006000 -835775000 -647574000
17 Zota Health Care Limited Laxmi Kant Sharma Executive Director Remuneration Noted 450000 84000 107000
18 Zota Health Care Limited Everyday Herbal Beauty Care Private Limited Subsidiaries Purchase of goods or services 800000000 Approved 50331000 9045000 11634000
19 Zota Health Care Limited Everyday Herbal Beauty Care Private Limited Subsidiaries Loan Noted 0 0 27745000 Loan 0.073 5 Unsecured The company is dealing into manufacturing of Khadi products and to carry out the said business they shall require funds in the form of working capital Textual Information(1)
20 Zota Health Care Limited Ashvin Variya Key Managerial Personnel Loan 3000000 Approved 1000000 2007000 3090000 Textual Information(2)
21 Everyday Herbal Beauty Care Private Limited Rajesh Vanechand Kubadiya Director of Subsidiary Remuneration Noted 750000 50000 100000
22 Everyday Herbal Beauty Care Private Limited Arvind Vanechand Kubadiya Director of Subsidiary Remuneration Noted 750000 50000 100000
23 Davaindia Health Mart Limited Hakishan Ambaram Jani Director of Wholly Owned Subsidiay Remuneration Noted 522000 92000 102000
24 Zota Health Care Limited Davaindia Health Mart Limited Subsidiaries Loan Noted 344382000 -224779000 -591094000 Textual Information(3)
25 Zota Health Care Limited Dhaval Chandubhai Patwa Non- Executive Independent Director Any other transaction Sitting Fees Noted 56000 18000 9000
26 Zota Health Care Limited Stuti Moxesh Zota Director's immediate relative Any other transaction Salary Salary upto Rs. 1 lakh per month 225000 38000 38000
27 Zota Health Care Limited Davaindia Health Mart Limited Subsidiaries Investment Noted 553994000 0 0 Investment 0 0 Unsecured Davaindia Health Mart Limited have been looking for aggressive expansion of COCO stores throughout India and the said investment has been made to mitigate the said fund requirements Textual Information(4)
28 Zota Health Care Limited Everyday Herbal Beauty Care Private Limited Subsidiaries Any other transaction Corporate Guarantee 65600000 Approved 0 65600000 65600000
29 Everyday Herbal Beauty Care Private Limited Rajesh Vanechand Kubadiya Director of Subsidiary Loan Noted 2631000 0 2631000 Loan 0.074 3 Unsecured Personal requirement Textual Information(5)
30 Davaindia Health Mart Limited Vitrag Sureshkumar Modi Independent Director of Wholly Owned Subsidiary Any other transaction Sitting Fees Noted 35000 0 32000
Total value of transaction during the reporting period 1518921000



Text Block
Textual Information(1) The loan has been disbursed prior to the acquisition done by the Company Further, the loan amount includes principle outstanding and interest.
Textual Information(2) The loan amount includes principle outstanding and interest.
Textual Information(3) The loan amount includes principle outstanding and interest.
Textual Information(4) Equity Investments
Textual Information(5) The loan amount includes principle outstanding and interest